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Second malignancies in the context of lenalidomide treatment:
an analysis of 2732 myeloma patients enrolled to the Myeloma
XI trial
JR Jones1,2, DA Cairns3, WM Gregory3, C Collett3, C Pawlyn1,2, R Sigsworth3, A Striha3, R Henderson3, MF Kaiser1,2, M Jenner4, G Cook5,
NH Russell6, C Williams6, G Pratt7, B Kishore7, J Lindsay8, MT Drayson9, FE Davies1,10, KD Boyd2, RG Owen5, GH Jackson11 and
GJ Morgan1,10 on behalf of the NCRI Haemato-Oncology CSG
We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been
used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence
and pathology. After review, 104 SPMs were confirmed in 96 of 2732 trial patients. The cumulative incidence of SPM was 0.7% (95%
confidence interval (CI) 0.4–1.0%), 2.3% (95% CI 1.6–2.7%) and 3.8% (95% CI 2.9–4.6%) at 1, 2 and 3 years, respectively. Patients
receiving maintenance lenalidomide had a significantly higher SPM incidence overall (P= 0.011). Age is a risk factor with the highest
SPM incidence observed in transplant non-eligible patients aged 474 years receiving lenalidomide maintenance. The 3-year
cumulative incidence in this group was 17.3% (95% CI 8.2–26.4%), compared with 6.5% (95% CI 0.2–12.9%) in observation only
patients (P= 0.049). There was a low overall incidence of haematological SPM (0.5%). The higher SPM incidence in patients receiving
lenalidomide maintenance therapy, especially in advanced age, warrants ongoing monitoring although the benefit on survival is
likely to outweigh risk.
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INTRODUCTION
There have been significant improvements in the outcome of
patients with multiple myeloma (MM) in the last 15 years with the
median overall survival increasing from 3 years up to 8 years.1–3
The use of novel agents in combination with high-dose melphalan
and autologous stem cell transplant (ASCT) have been the main
reason for improved survival rates.1–4 However, relapse remains
frequent even in patients with favourable genetic profiles who
undergo intensive induction therapy and tandem ASCT.5 Relapse
is due to the persistence of malignant plasma cells, and as a
consequence long-term maintenance strategies to control residual
disease have been assessed.6
Historically, the use of interferon as maintenance was associated
with significant comorbidity and, therefore, is rarely utilised
despite evidence of potential survival benefits.7,8 In the era of
immunomodulatory agents, thalidomide and lenalidomide have
been assessed as maintenance options, but long-term thalidomide
is poorly tolerated, mainly due to peripheral neuropathy.9,10 In
contrast lenalidomide maintenance has been associated with a
manageable side-effect profile and significant improvements in
progression-free survival and overall survival in some studies.11–13
In the first trials that addressed the role of lenalidomide
maintenance in both transplant eligible (TE) and transplant non-
eligible (TNE) populations, an increased risk of second primary
malignancy (SPM) was noted.11–13 Rates of haematological SPM
were significantly higher in the lenalidomide-treated arms with
myelodysplastic syndrome, Hodgkin’s disease and acute myeloid
leukaemia being most commonly reported.11–13 Increased rates of
solid cancer were also reported but this was not consistently
significant. A recent meta-analysis of seven trials, totalling 3254
patients, found no difference in the incidence of solid tumours,
but rates of haematological malignancies were recorded at 3.1%
and 1.4% of patients treated with or without lenalidomide,
respectively.14 This increased rate was significant and seemed to
be linked to the use of oral melphalan combined with
lenalidomide.14 However, there was no increased risk associated
with lenalidomide alone or in combination with other agents,
including cyclophosphamide or intravenous melphalan-condi-
tioning pre-transplant.
It is clear that more data are required to define the true impact
of lenalidomide on SPM development, particularly in relation to
the impact of concomitant therapies received, the duration of
therapy and the effect of age. We aimed to accurately determine
the overall and treatment-specific SPM incidence in patients
enrolled to the Myeloma XI trial. The trial comprises both TE and
TNE pathways with randomisation to induction and maintenance
regimes containing lenalidomide. In addition, we utilised a
clinician-led SPM committee review process in which all suspected
SPM reported in patients enrolled to the trial are reviewed before
they were confirmed as trial-related.
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PATIENTS AND METHODS
Study design and participants
Myeloma XI is a phase III, randomised, multi-centre, parallel-group design,
open-label trial comparing thalidomide, lenalidomide and bortezomib
induction combinations and lenalidomide± vorinostat as maintenance in
newly diagnosed myeloma patients aged 18 years or over (NCT01554852).
Inclusion and exclusion criteria are outlined (Supplementary Table 1). The
trial included both TE and TNE pathways. This analysis reports new primary
malignancies observed in patients enrolled before an amendment to add a
carfilzomib-based quadruplet as an induction option for TE patients in
June 2013. Data cutoff for this analysis was 23 July 2015.
All patients underwent randomisation (1:1) to cyclophosphamide,
thalidomide and dexamethasone (CTD), or cyclophosphamide, lenalido-
mide and dexamethasone (RCD). Patients in the TNE pathway received
attenuated dosing regimens. After initial randomisation, patients con-
tinued induction treatment until maximum response or intolerance. All
patients received a minimum of six cycles before entering either
maintenance (TNE) or four cycles before ASCT (TE). Patients continued to
ASCT (TE) or maintenance randomisation (TNE) if a very good partial
response or better was achieved following induction.
Patients who had a minimal response (MR) or partial response following
induction underwent a further 1:1 randomisation to bortezomib, cyclopho-
sphamide and dexamethasone (CVD) or nothing. Patients who had no
change or progressive disease (PD) following induction received CVD on
protocol. Up to eight cycles of CVD were administered and if an MR or
better was observed patients continued to ASCT (TE) or maintenance
randomisation (TNE). Patients who had evidence of PD or no change
following this were treated off protocol. Response to treatment was
assessed using the International Uniform Response Criteria for Multiple
Myeloma.15
One hundred days post high-dose melphalan and ASCT, eligible patients in
the TE pathway entered maintenance randomisation. TNE patients were
randomised following induction or CVD. Randomisation resulted in entry to
one of three regimes; single-agent lenalidomide, lenalidomide and the
histone deacetalayse inhibitor vorinostat or observation only (Supplementary
Figure 1).
Patients were reviewed at least four weekly during induction. During the
maintenance phase monthly follow-up was arranged for those on
lenalidomide-based therapy and two monthly for those under active
observation. Maintenance lenalidomide ± vorinostat was administered for
21 days of a 28-day cycle. After 2 years of maintenance patients under
active observation had their monitoring frequency reduced to three
monthly whilst those on lenalidomide continued with monthly review
(Supplementary Table 2).
Centres were required to report all SPMs in patients who entered the
trial until death irrespective of whether they were still on the trial or not.
Study characteristics
In all, 2745 patients entered the trial with 2732 receiving at least one dose
of protocol treatment between May 2010 and June 2013. Of the 2732
patients that initiated treatment, 1509 and 1223 entered the TE and TNE
pathways, respectively. Within the TE pathway 753 patients received CTD
induction and 756 received RCD induction. In the TNE pathway 612
patients received CTDa and 611 received RCDa. A total of 1362 patients
continued to maintenance randomisation with 832 receiving lenalidomide,
527 as a single agent and 305 in combination with vorinostat
(lenalidomide plus vorinostat). In all, 530 were randomised to active
observation. The median follow-up since trial entry and maintenance
randomisation is 34.3 and 24.2 months, respectively. The median age of
patients enrolled to the TE and TNE pathways was 61 years (range 28–75)
and 74 years (range 51–89), respectively (Table 1).
Outcomes
The primary end points were overall survival and progression-free survival,
and it is anticipated that these will be reported from 2016 onwards. Here
we report an interim analysis of SPM incidence as a key safety end point.
All reported SPMs were reviewed and a clinical narrative summarising
each case was completed. Additional information was requested from
reporting centres, including histological reports, clinic letters and past
medical history. All cases were presented to a committee of five clinicians
(JJ, GJM, GHJ, RO and KB) with a chair independent of the trial
management group (KB, chair of the Myeloma XI independent trial
steering committee). Each case was discussed and a decision was made
whether to confirm or reject the SPM. Criteria for rejection are outlined
(Table 2). Where a decision could not be made additional information was
sought and the case re-discussed until resolution. A unanimous committee
decision was required to reject any suspected SPM. A minimum of four
committee members were required for the session to be quorate.
Statistical analysis
All statistical analyses were undertaken in SAS (version 9.4; SAS Institute,
Cary, NC, USA) according to the Myeloma XI Trial Statistical Analysis Plan.
SPM diagnosed after trial entry was summarised for all patients.
Cumulative incidence function curves were estimated by non-parametric
maximum likelihood estimation16 and plotted overall, by pathway and by
treatment arm. The Pepe-Mori test17 for equality of cumulative incidence
functions was used to analyse time to first SPM with unrelated deaths as a
competing risk. Fine and Gray competing risks regression18 was used to
compare the hazard of SPMs by treatment adjusting for the minimisation
factors (β-2 microglobulin, haemoglobin, serum creatinine and calcium
concentration, and platelets count at trial entry and earlier randomised
treatment at consolidation and maintenance randomisation—stratified by
pathway, where appropriate) with unrelated deaths specified as a
competing risk. Person-years on trial was calculated as the sum over all
patients receiving at least one dose of study treatment of the time in years
from randomisation to death or last date known to be alive. Incidence rates
were calculated with the number of events as the numerator and the
number of person-years on trial as the denominator. Confidence intervals
for incidence rate were calculated using approximations for the Poisson
distribution. The analysis of primacy was predefined in the Statistical
Analysis Plan to be the Fine and Gray regression. All statistical tests were
two-sided and called significant at the 5% level.
Table 1. Induction and maintenance therapy received for all patients who received at least one dose of a study drug
Treatment phase Regime Median age (range) Patients (n)
Induction CTD 61.0 (29.0, 73.0) 753
RCD 61.0 (28.0, 75.0) 756
CTDa 74.0 (51.0, 88.0) 612
RCDa 74.0 (60.0, 89.0) 611
Total 2732
Median follow-up from trial entry 2.9 years (IQR 2.0–3.5)
Maintenance Lenalidomide 66.0 (29.0, 89.0) 527
Lenalidomide plus vorinostat 66.0 (35.0, 86.0) 305
Observation 66.0 (30.0, 90.0) 530
Total 1362
Median follow-up from maintenance randomisation 2.0 years (IQR 1.2–2.8)
Abbreviations: CTD, cyclophosphamide, thalidomide and dexamethasone; RCD, cyclophosphamide, lenalidomide and dexamethasone.
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RESULTS
We identified 128 suspected SPMs in 114 patients. Following
review, 24 (18.8%) in 18 patients were rejected. The reasons for
rejection were the following: evidence existed to suggest the
malignancy was present before enrolment (n= 14); initial report
found to be incorrect (n= 4); pre-malignant/benign skin condi-
tions (n= 4); recurrence of previous malignancy (n= 1); and
spontaneous resolution of disease (reversal of cytopenia following
treatment cessation) (n= 1). A total of 104 SPMs in 96 patients
were confirmed as trial-related. Of those confirmed, 4 patients had
developed 2 separate malignancies, 2 patients developed 3
separate malignancies and the remainder a single malignancy.
The median age at SPM diagnosis was 72 years and the median
time to diagnosis from induction randomisation was 22.3 months
(range 3.4–51.8).
In all, 40 SPMs in 35 patients were diagnosed in patients
enrolled to the TE pathway and 64 SPMs in 61 patients were
diagnosed in patients enrolled to the TNE pathway (Figure 1). The
median time to SPM diagnosis from induction randomisation was
24.3 (range 3.6–46.6) and 20.6 (range 3.4–51.8) months for the TE
and the TNE pathways, respectively. The median age at time of
SPM diagnosis was 69 years (range 58–76) for the TE pathway
and 76 years (range 54–90) for the TNE pathway. In all patients
the median number of induction cycles was 6 For CTD, CTDa
and RCDa, and 5 for RCD. Transplant non-eligible patients
randomised to lenalidomide maintenance (± vorinostat) received
a median of 14 cycles (range 1–42) of maintenance and those in
the TE pathway also received a median of 14 cycles (range 1–48;
Table 3).
Overall SPM incidence
The overall trial-related SPM incidence was 3.8% at 3 years (2.7%
TE and 5.2% TNE). The cumulative incidence of SPM in the whole
trial population was 0.7% (95% confidence interval (CI) 0.4–1.0%),
2.3% (95% CI 1.6–2.7%) and 3.8% (95% CI 2.9–4.6%) at 1, 2 and 3
years, respectively (Figure 2a). If non-invasive, non-melanoma skin
cancers (NMSCs) were excluded, the 1-, 2- and 3-year cumulative
incidence falls to 0.6% (95% CI 0.3–0.9%), 1.8% (95% CI 1.3–2.3%)
and 2.9% (95% CI 2.2–3.6%), respectively (Figure 2b). Thirty six
(35%) of the 104 SPM were non-invasive NMSC. SPM incidence
rate per 100 person-years was 1.6 overall. Incidence rate per 100
patient-years for the TE and TNE pathways was 1.0 and 2.5,
respectively (Table 3).
Lenalidomide versus thalidomide induction
The 3-year SPM cumulative incidence for patients in the TE
pathway who received RCD (24 SPMs, 22 patients) and CTD (16
SPMs, 13 patients) induction was 2.7% (95% CI 1.4–4.0) and 1.5%
(95% CI 0.5–2.5), respectively (Pepe-Mori P= 0.016; adjusted
hazard ratio (HR) 1.74 (95% CI 0.88–3.45), Fine and Gray
P= 0.114; Figure 3a). In patients enrolled to the TNE pathway
the 3-year SPM cumulative incidence was 5.9% (95% CI 3.7–8.1)
versus 5.9% (95% CI 3.7–8.2) for those receiving RCDa (30 SPMs, 28
patients) and CTDa (34 SPMs, 33 patients), respectively (Pepe-Mori
P= 0.220; adjusted HR 0.86 (95% CI 0.52–1.42), Fine and Gray
P= 0.548; Figure 3b).
Lenalidomide maintenance versus observation
For all patients randomised to maintenance, the 3-year cumulative
incidence for those who received lenalidomide ( ± vorinostat, 42
SPMs, 40 patients) versus active observation (16 SPMs, 15 patients)
was 8.9% (5.9–11.8%) and 4.0% (1.8–6.2%), respectively (Pepe-
Mori P= 0.006; adjusted HR for lenalidomide versus active
observation 2.46 (95% CI 1.16–5.21), P= 0.183; adjusted HR for
lenalidomide plus vorinostat versus active observation 2.03 (95%
CI 1.08–3.79), P= 0.027; adjusted HR for lenalidomide ± vorinostat
2.14 (95% CI 1.19–3.85), Fine and Gray P= 0.011; Figure 4a).
For patients enrolled to the TE pathway the 3-year cumulative
incidence for those who had been randomised to maintenance
and received lenalidomide ( ± vorinostat, 13 SPMs, 13 patients)
versus active observation (5 SPMs, 4 patients) was 5.8% (95% CI
2.1–9.4) and 2.0% (95% CI 0.0–4.1), respectively (Pepe-Mori
P= 0.006; adjusted HR for lenalidomide versus active observation
1.65 (95% CI 0.46–6.00), Fine and Gray P= 0.444; adjusted HR for
lenalidomide plus vorinostat versus active observation 5.21 (95%
CI 1.53–17.2), Fine and Gray P= 0.008; adjusted HR for lenalido-
mide ± vorinostat 2.58 (95% CI 0.84–7.86), Fine and Gray P= 0.097;
Figure 4b).
Three-year cumulative incidence for lenalidomide maintenance
( ± vorinostat, 29 SPMs, 27 patients) versus active observation (11
SPMs, 11 patients) in the TNE pathway was 12.9% (95% CI 7.9–
17.9) and 6.3% (95% CI 2.3–10.2), respectively (Pepe-Mori P= 0.04;
adjusted HR for lenalidomide versus active observation 2.18 (95%
CI 1.04–4.54), Fine and Gray P= 0.038; adjusted HR for lenalido-
mide plus vorinostat versus active observation 1.48 (95% CI 0.52–
4.20), Fine and Gray P= 0.459; adjusted HR for lenalidomide±
vorinostat 2.01 (95% CI 0.99–4.07), Fine and Gray P= 0.053;
Figure 4c).
The SPM incidence rate per 100 person-years was 2.2 overall.
The incidence rate per 100 person-years for the TE and TNE
Table 2. SPM rejection criteria
1 Evidence exists that the malignancy was present before trial entry. Examples include the following:
Imaging from screening or pre-screening confirms the presence of a lesion picked up later in the trial
In the case of prostate cancer, PSA measurements taken before trial enrolment were elevated
In the case of skin cancers there is documented evidence that confirms the lesions were present before enrolment, for example, GP letters
2 Pre-malignant/benign conditions such as solar keratosis and actinic keratosis are excluded
3 Any malignancy diagnosed during the first cycle is deemed to not be treatment related. This is on the basis that treatment exposure has not
been long enough for a new malignancy to develop and progress enough to cause symptoms.
4 Recurrence of a previous malignancy
Any malignancy that occurs again within 5 years should not be classed as a trial-related SPM
5 Initial report found to be incorrect
Cases initially reported as being a malignancy may subsequently be found to be either benign or infective. These cases are also reviewed by the
committee
6 Spontaneous resolution of disease
Examples include resolution of drug- or disease-related cytopenia
Abbreviations: GP, general practitioner; PSA, prostate specific antigen; SPM, second primary malignancy. If any one of the above criteria were met the SPM was
rejected.
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patients in the maintenance phase was 1.2 and 3.6, respectively.
Patients in the TE pathway receiving lenalidomide, lenalidomide
plus vorinostat and observation had an incidence rate per 100
patient years of 1.0, 2.4 and 0.8, respectively. Patients in the TNE
pathway receiving lenalidomide, lenalidomide plus vorinostat and
observation had an incidence rate per 100 patient years of 5.5, 2.9
and 2.2, respectively (Table 3).
Lenalidomide maintenance in advanced age
The median age of the TNE patients was 74 years and, therefore,
this was used as a cutoff for determining advanced age. The 3-
year SPM cumulative incidence for patients in the TNE pathway
aged 474 years who received lenalidomide ( ± vorinostat, 17
SPMs, 16 patients) maintenance versus active observation (6 SPMs,
6 patients) was 17.3% (95% CI 8.2–26.4) and 6.5% (95% CI 0.2–
12.9), respectively (Pepe-Mori P= 0.072, adjusted HR for lenalido-
mide ± vorinostat 1.378 (0.529–3.591), Fine and Gray P= 0.049;
Figure 5a). For TNE patients ⩽74 years the SPM cumulative
incidence for those receiving lenalidomide (± vorinostat) main-
tenance versus active observation was 9.7% (95% CI 4.3–15.1) and
6.1% (95% CI 1.2–11.0), respectively (Pepe-Mori P= 0.129, adjusted
HR for lenalidomide ± vorinostat 3.059 (1.003–9.330), Fine and
Gray P= 0.511; Figure 5b).
The median number of maintenance cycles received was 23 in
those ⩽74 and 12 in those 474. The median total dose of
lenalidomide per patient in these two groups was 3360 mg (range
180–21 105 mg) and 2273 mg (range 840–17 430 mg) for those
⩽ 74 and 474, respectively (Table 2).
Pathological breakdown of SPM
SPMs were classified as either invasive haematological, invasive
solid malignancies, including melanoma skin cancer, or non-
invasive, NMSCs. Almost two-thirds (65%) of all SPMs were
invasive with 68 cases in 68 patients. Twenty-nine cases were
diagnosed in patients enrolled to the TE pathway and 39 in
patients enrolled to the TNE pathway giving an incidence of 1.9%
and 3.2% for the TE and TNE pathway, respectively (Supple-
mentary Table 3).
Thirteen confirmed haematological SPMs in 13 patients were
observed during the trial. Of the 13, 10 cases were observed in
patients enrolled to the TE pathway and 3 cases were observed in
patients enrolled to the TNE pathway. In all, 6 patients developed
myelodysplastic syndrome, 3 acute myeloid leukaemia, 2 non-
Hodgkin lymphoma, 1 Hodgkin lymphoma and 1 chronic myeloid
leukaemia. The trial incidence of haematological SPM was 0.48%.
Cumulative incidence was 0%, 0.2% (95% CI 0.1–0.4%) and 0.4%
(95% CI 0.1–0.7%) at 1, 2 and 3 years, respectively. Of the 10 SPMs
in the TE pathway 8 patients had been exposed to lenalidomide
and 5 patients received lenalidomide maintenance. Of the 3 SPMs
in patients in the TNE pathway all had been exposed to
lenalidomide and 2 received lenalidomide maintenance. The
median age at the time of SPM diagnosis was 68 years, and
median time to diagnosis from induction randomisation was
25.9 months (range 12.4–44.5).
A total of 55 solid malignancies in 55 patients were confir-
med as trial-related resulting in an incidence of 2.0%. The
median time to SPM diagnosis was 20.5 months (range
3.4–45.8). In all, 19 solid SPMs were observed in patients
enrolled to the TE pathway and 36 were observed in patients
Observation
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RCD (756)CTD (753)
Randomise
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Maintenance randomisation
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(1223)
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RCD only 
12 SPM
Observation
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Lenalidomide
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Figure 1. Consort diagram outlining the treatment pathway for all 104 SPMs confirmed as trial-related.
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enrolled to the TNE pathway. The median age of SPM diagnosis
was 67 years and 75 years for the TE and TNE pathways,
respectively. The median time to SPM diagnosis from
induction randomisation was 20.3 months for those in the TNE
pathway and 21 months for those in the TE pathway. Twenty
different types of solid malignancy were diagnosed. Histo-
Table 3. Summary of SPM cumulative incidence and significance at 3 years according to pathway and treatment received
SPM incidence at 3 years according to treatment Incidence
Whole trial P-valuea TE P-valuea TNE P-valuea
Induction (104 SPMs)
Whole trial cohort all SPM (%) 3.8 — — —
Lenalidomide induction (%) 3.7 40.05 2.7 0.114 5.9 0.548
Thalidomide induction (%) 3.4 1.5 5.9
Maintenance (58 SPMs)
Lenalidomide± vorinostat maintenance (%) 8.9 0.011 5.8 0.1 12.9 0.053
Observation only (%) 4.0 2.0 6.3
TNE ⩽ 74 years observation only (%) — — 6.1 0.511
TNE ⩽ 74 years lenalidomide± vorinostat (%) 9.7
TNE 474 years observation only (%) — — 6.5 0.049
TNE 474 years lenalidomide± vorinostat (%) 17.3
SPM incidence per 100 person-years according to induction
Overall 1.6 — 1 — 2.5 —
Thalidomide induction — 0.8 2.7
Lenalidomide induction — 1.2 — 2.3 —
SPM incidence per 100 person-years according to maintenance
Overall 2.2 — 1.2 — 3.6 —
Active observation — 0.8 — 2.2 —
Lenalidomide 1 — 5.5 —
Lenalidomide+vorinostat 2.4 — 2.9 —
Cycles all Cycles TE Cycles TNE
Number of cycles of therapy received in all SPM patients
Median number of induction cycles (range) 6 (1–14) CTD= 6 (3–8) CTDa= 6 (1–8)
RCD= 5 (4–14) RCDa= 6 (1–8)
Median number of maintenance cycles (range) 14 (1–48) 14 (1–42) 14 (1–48)
mg all (range) mg TE (range) mg TNE (range)
Total induction drug doses received in all SPM patients
Median total cyclophosphamide dose per patient 6000 (0–16 000) 6000 (3100–12 000) 6400 (0–16 000)
Median total dexamethasone dose per patient 960 (80–4000) 1280 (640–4000) 960 (80–1280)
Median total thalidomide dose per patient 14 000 (800–32 000) 15 000 (6300–32 000) 12 000 (800–28 000)
Median total lenalidomide dose per patient 2100 (165–7350) 2100 (1240–7350) 2118 (165–3150)
Total maintenance drug doses received in all SPM patients
Median total lenalidomide maintenance dose per patient 3080 (180–21 105) 3448 (210–13 075)b 2940 (180–21 105)
TNE overall mg
(range)
TNE ⩽ 74 years mg
(range)c
TNE 474 years mg
(range)
TNE median total lenalidomide maintenance dose per patient
according to age
2940 (180–21 105) 3360 (180–21 105) 2273 (840–17 430)
Abbreviations: CTD, cyclophosphamide, thalidomide and dexamethasone; RCD, cyclophosphamide, lenalidomide and dexamethasone; SPM, second primary
malignancy; TE, transplant eligible; TNE, transplant non-eligible. There was a significant difference between SPM incidence at 3 years in patients receiving
lenalidomide-based maintenance compared with patients being observed only for the whole trial cohort (P= 0.011). There was also a significant difference in
SPM incidence in patients 474 years, enrolled to the TNE pathway who received lenalidomide maintenance in comparison with the observation group
(P= 0.049). Overall trial SPM incidence per 100 person-years is 1.6. Transplant eligible patients have a lower total SPM incidence in comparison with the TNE
patients (1.0 versus 2.5). Incidence rates per 100 person-years according to induction therapy were 0.8 and 1.2 for patients receiving thalidomide versus
lenalidomide in the TE pathway. The TNE pathway patients receiving thalidomide or lenalidomide induction had incidence rates per 100 person-years of 2.7
and 2.3, respectively. Fifty-eight patients developed a second malignancy whilst in the maintenance phase of the trial resulting in an incidence rate (IR) of 2.2
per 100 person-years. Eighteen patients developed an SPM following maintenance randomisation in the TE arm and 40 in the TNE arm with an IR per 100
patient-years of 1.2 and 3.6, respectively. The lowest incidence was observed in patients being observed only, with TE and TNE IR per 100 patient years of 0.8
and 2.2, respectively. Patients receiving lenalidomide alone or in combination with vorinostat had incidence rates of 1.0 and 2.4 per 100 patient years,
respectively, in the TE pathway, and 5.5 and 2.9, respectively, in the TNE pathway. The number of induction cycles received was comparable between groups
with a median of 6 cycles for CTD, CTDa and RCDa, and 5 cycles for RCD. Total doses of trial drugs received at induction and maintenance was also comparable
between SPM patients according to pathway and age. Patients 474 years in the TNE pathway who received lenalidomide maintenance and developed an
SPM did not receive greater doses of trial drug in comparison to those o74 years. aFine and Gray. bTotal dose of lenalidomide maintenance received was not
available for one patient in the TE pathway. cTotal dose of lenalidomide maintenance received was not available for one patient ⩽ 74 years in the TNE pathway.
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logical confirmation was available for 52 of the 55 SPM with
imaging indicating widespread metastatic disease in the other
three. The most frequent malignancies observed were breast
(7 cases), colon, (7 cases), prostate (6 cases), lung (5 cases) and
bladder (4 cases) (Supplementary Table 4).
Approximately one-third (35%) of cases were low-risk NMSCs
with 36 cases diagnosed in 30 patients. Twenty-five NMSCs were
observed in 23 patients enrolled to the TNE pathway with a
median time to diagnosis from induction randomisation of
25.7 months and a median age of 78 years. Ten cases were basal
cell carcinoma and 15 were squamous cell carcinoma. Eleven
NMSCs developed in seven patients enrolled to the TE pathway
with a median time to diagnosis of 33.7 months and a median
age of 71. Eight cases were basal cell carcinoma and three were
squamous cell carcinoma.
Deaths after SPM and development in relation to myeloma
progression
Of the 104 SPM cases diagnosed, 69 cases (66%) in 61 patients
occurred before PD. Thirty-eight patients diagnosed with a trial-
related SPM have subsequently died (39.6%). Of these, 13 deaths
were in patients enrolled to the TE pathway, 5 having received
CTD and 8 RCD induction. The remaining 25 deaths occurred in
patients enrolled to the TNE pathway with 15 patients having
received CTDa and 10 RCDa induction. Nineteen (50%) deaths
were observed in patients who had undergone maintenance
Cumulative incidence
Overall
Cumulative incidence
Overall
1 year 0.7%
2 years 2.3%
3 years 3.8%
1 year 0.6%
2 years 1.8%
3 years 2.9%
Figure 2. (a) Overall trial-related SPM incidence. The 1-, 2- and 3-year cumulative incidence of all SPM is 0.7%, 2.3% and 3.8% at 1, 2 and 3
years, respectively, for the whole trial. (b) Overall-trial related SPM incidence excluding NMSC. The 1-, 2- and 3-year cumulative incidence of all
SPM when non-invasive malignancies are excluded is 0.6%, 1.8% and 2.9%, respectively, for the whole trial.
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randomisation, 15 in patients randomised to lenalidomide and 4
in patients being observed. Of the 38 deaths, 6 patients (23.7%)
had PD related to myeloma at the time of death. Cause of death
due to second malignancy was noted in 27 (71.1%) patients
resulting in an overall trial SPM mortality of 1%. Death due to
cardiac, respiratory and ‘non-myeloma’-related factors was noted
as the cause of death for the remaining 5 patients.
DISCUSSION
The overall incidence rate of SPM observed on trial is low with a
3-year cumulative incidence of 3.8%, an overall incidence of 3.8%
of treated patients and an incidence rate of 1.6 per 100 person-
years. This is consistent with other studies in which lenalidomide
has been used as a maintenance option in combinations
excluding oral melphalan and markedly less than the 6.7 and
6.8% 3 year SPM incidence seen in the early studies where
lenalidomide was used in combination with melphalan.11–13,19,20
An effect of age and perhaps comorbidity is suggested by the
higher overall SPM incidence in the TNE patients where overall
SPM incidence was 5.2% in contrast to 2.7% in TE patients.
Lenalidomide as a long-term treatment option in TNE patients has
been assessed previously using both continuous and intermittent
dosing schedules. In one such study the use of continuous
lenalidomide and dexamethasone was associated with a 3-year
invasive SPM incidence of 3%, similar to the 3.1% TNE pathway
invasive SPM incidence observed here.20 The median ages of
patients were also comparable. This perhaps suggests that the use
3 year CI
RCD – 2.7%
CTD – 1.5%
p = 0.114
3 year CI
RCDa – 5.9%
CTDa – 5.9%
p = 0.548
Figure 3. (a) TE pathway SPM incidence according to induction. Three-year SPM CI was 2.7% and 1.5% for the RCD and CTD induction groups,
respectively; Fine and Gray P= 0.014. n= 756 RCD and 753 CTD. (b) TNE pathway SPM incidence according to induction. Three-year SPM CI
was 5.9% and 5.9% for the RCDa and CTDa groups, respectively; Fine and Gray P= 0.548. n= 611 RCDa and 612 CTDa.
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of interrupted lenalidomide has no impact on SPM incidence rates
in comparison with continual dosing. The median total dose of
drugs administered in the early trials is not reported but in our
study the doses were comparable between groups and in the TNE
group where a higher SPM incidence was observed there was no
evidence of greater drug exposure. This again suggests that other
factors such as age, rather than drug exposure alone are factors in
SPM development. The link between skin cancer development
and immunosuppression is well established and thus the finding
that 35% (n= 36) of cases were NMSCs is not surprising.21 The
3-year cumulative incidence of SPM falls to 2.9% when NMSCs are
excluded.
3 year CI
Len – 8.9%
Obs – 4.0%
p = 0.011
3 year CI
Len – 5.8%
Obs – 2.0%
p = 0.097
3 year CI
Len –12.9%
Obs – 6.3%
p = 0.053
Figure 4. (a) Whole trial SPM incidence according to maintenance received. Three-year CI was 8.9% and 4.0% for the len and active
observation maintenance groups, respectively; Fine and Gray P= 0.011. n= 820 len± vori and 540 active observation. (b) TE pathway SPM
incidence according to maintenance received. Three-year CI was 5.8% and 2.0% for the len and active observation maintenance groups,
respectively; Fine and Gray P= 0.097. n= 495 len± vori and 313 active observation. (c) TNE pathway SPM incidence according to maintenance
received. Three-year CI was 12.9% and 6.3% for the len and active observation maintenance groups, respectively; Fine and Gray P= 0.053.
n= 324 len± vori and 228 active observation. len, lenalidomide; vor, vorinostat.
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In relation to lenalidomide exposure 73 SPM (70%) were
observed in patients exposed to lenalidomide either during
induction (n= 31), maintenance (n= 23) or both (n= 19). Thirty-
one patients (30%) had received thalidomide only. In the trial 50%
of patients receive a lenalidomide-based induction with two-thirds
of maintenance eligible patients receiving lenalidomide main-
tenance. It is, therefore, not unexpected that more patients have
been exposed to lenalidomide therapy. This may in part explain
the significantly higher SPM incidence observed in patients who
received lenalidomide maintenance (P= 0.011). However, it is
more likely that the higher incidence is due to a combination of
factors, including the impact of secondary immunodeficiency
developed as a consequence of myeloma, cytotoxic and
immunomodulatory therapy, and advancing age. SPM incidence
in patients receiving lenalidomide maintenance was not signifi-
cantly higher when broken down according to pathway (P= 0.097
and 0.053 for TE and TNE pathways, respectively), although this is
most likely due to insufficient power, illustrated by the signifi-
cantly higher incidence when the pathways are combined
(P= 0.011). It is also noted that the type of induction therapy
received had no significant impact on SPM incidence. Three-year
cumulative incidence of SPM for TE patients who received RCD
was 2.7% as compared with 1.5% for those who received CTD
(P= 0.114). For patients in the TNE pathway 3-year SPM cumulative
3 year CI
Len – 17.3%
Obs – 6.5%
p = 0.049
3 year CI
Len – 9.7%
Obs – 6.1%
p = 0.511
Figure 5. (a) TNE patients 474 years old receiving maintenance. Overall 3-year CI was 17.3% and 6.5% for the len and active observation
maintenance groups, respectively; P= 0.049. n= 144 len and 103 obs. (b) TNE patients ⩽74 years old receiving maintenance. Overall 3-year CI
was 9.7% and 6.1% for the len and active observation maintenance groups, respectively; P= 0.511. n= 180 len and 125 obs. len, lenalidomide;
obs, observation.
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incidence was 5.9% versus 5.9% for RCD and CTD (P= 0.548). This
again suggests that treatment duration is likely to be a risk factor
for second malignancy development.
Solid malignancies constitute the majority of confirmed trial-
related SPM. In total 55 patients developed a solid cancer, and the
spectrum of cases seen was as seen in the general population. The
four most commonly reported SPMs were breast, colon, prostate
and lung, consistent with the distribution of types in the UK
population.22 There was a higher overall incidence observed in the
TNE group in comparison with the TE group, 2.9% versus 1.3%,
which is likely to be secondary to the age effect. The overall
incidence of trial-related solid malignancies was 1.5%, consistent
with other trials in which lenalidomide has been a therapeutic
option.12,13,23
An increased incidence of haematological SPM was not seen
here.11–13 Thirteen patients developed a second haematological
malignancy giving an overall incidence of 0.48%, consistent with
recent meta-analysis.14 The overall haematological SPM incidence
was 0.8% and 0.2% for the TE and TNE pathways, respectively.
Although the overall incidence of haematological SPM in the TE
pathway is low it is still evident that 10 of the 13 confirmed cases
occurred in that pathway. All of these patients received melphalan
conditioning before stem cell return. Myelodysplastic syndrome
developed in six patients enrolled on the TE pathway, and five of
these patients had received lenalidomide either at induction
(n= 1), maintenance (n= 3) or both (n= 1). The significance of this
observation is not clear.24,25 Three cases of acute myeloid
leukaemia were confirmed, one in the TE pathway and two in
the TNE pathway. We did not see an excess of B-cell malignancies.
There were two trial-related diffuse large B-cell lymphoma cases
and one Hodgkin lymphoma. The final haematological SPM case
diagnosed during the trial was a chronic phase myeloid
leukaemia.
A known risk factor for the development of malignancy in the
general population is age, and consistent with this 64 of the 104
(62%) confirmed SPMs were diagnosed in patients enrolled to the
TNE pathway giving a higher overall incidence in the TNE pathway
of 5.2% versus 2.7% in the TE pathway. We used the median TNE
patient age as a cutoff in the group to determine older age and
noted an increase in SPM incidence after 2 years in this group. At 3
years the cumulative incidence of SPM in patients 474 years
receiving lenalidomide maintenance was 17.3% versus 6.5% in
patients randomised to active observation (P= 0.049). Only 43
patients, 19 receiving lenalidomide and 24 being monitored, had
reached 3-year post maintenance randomisation in the TNE
pathway at the time of data cutoff. Reassuringly, 8 of the 17 SPMs
diagnosed in this group were non-invasive NMSCs. Of the
remaining 9 SPMs, 7 were solid malignancies and 2 were
haematological (both acute myeloid leukaemia).
In addition, there may be some confounding factors influencing
the true rate of SPM incidence in the active observation arm. The
trial protocol requires patients on lenalidomide (± vorinostat)
maintenance to be reviewed every 4 weeks whilst those being
observed are seen a maximum of every 8 weeks. Reduced clinic
time may result in under-reporting by patients. Patients receiving
treatment may also be more vigilant for new symptoms or signs,
especially in those informed of previous reports of a link between
lenalidomide and SPM development.
Mortality as a consequence of second malignancy was observed
in 27 patients resulting in an overall incidence of 1.0%. Only 6 of
these patients had progressive myeloma at the time of death.
With such a low overall death rate attributable to second
malignancies the benefit of lenalidomide therapy is likely to
significantly outweigh treatment-related SPM risk. These data
support meta-analysis findings, where the SPM death rate
observed in patients receiving lenalidomide was 1.0% compared
with 0.7% in those not.14
An important lesson learnt from this study is the timing of
second cancer incidence and its relation to trial entry. Many
cancers, particularly in the older age group, were diagnosed early
in trial follow-up, consistent with them having being present at
trial entry. We have demonstrated the importance of a detailed
review of all suspected SPM reported in patients enrolled to trials.
Almost one-fifth of cases (n= 24, 18.8%) were rejected, impacting
on the overall incidence of cases. The majority of these cases
(n= 14, 58%) were rejected because there was clear evidence that
the second malignancy was present before enrolment. We believe
that a review process should be incorporated into all trials, where
second malignancies are considered a possible risk. The decision
to reject or accept SPM as trial-related should be determined by
specific pre-determined criteria. On initiation of treatment all
patients should undergo a full systems examination, including the
skin, to look for signs of possible existing malignancy. In addition,
a medical history inclusive of a systems review should be
conducted to determine symptoms consistent with possible
underlying additional pathologies. Given the incidence of NMSC
in this study and others, all patients on active treatment should be
asked about the development of new skin lesions on each visit.
Skin examination should be conducted at a minimum of three
times per year. All patients should be warned of the possible long-
term effects of maintenance therapy, irrespective of its nature and
followed up appropriately. The majority of solid malignancies
were those commonly seen in the ageing population, for example,
colon/small bowel, prostate, breast and lung.
In summary, overall SPM incidence in association with the trial
has been low. Overall, there is an increased incidence of SPM at 3
years in patients receiving lenalidomide compared to observation
only. A significantly higher SPM incidence is seen in older patients
on maintenance lenalidomide compared with those being
observed. An increased incidence of haematological malignancies
in association with long-term lenalidomide has not been
observed. Although low, there is an increased incidence of
haematological malignancies in patients who have undergone
stem cell transplantation perhaps secondary to melphalan use.
Death as a consequence of second malignancy is very low and the
survival benefit provided by myeloma therapy outweighs this risk.
The incorporation of an SPM review process has been successful
and should be incorporated into future trials in which SPM are
deemed a significant risk.
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